- $31.36m
- $24.46m
- $7.53m
Evaxion A/S expected to post a loss of 66 cents a share - Earnings Preview
Evaxion A/S expected to post a loss of 66 cents a share - Earnings Preview
Brief: Evaxion A/S - Christian Kanstrup Steps Down As CEO
Brief: Evaxion A/S Expands Research And Development Pipeline With New Vaccine Program Targeting Group A Streptococcus
Evaxion A/S reports results for the quarter ended March 31 - Earnings Summary
Evaxion A/S expected to post a loss of 65 cents a share - Earnings Preview
Brief: Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01
Evaxion Biotech A/S reports results for the quarter ended December 31 - Earnings Summary
Evaxion Biotech A/S expected to post a loss of $3.88 a share - Earnings Preview
Evaxion Biotech A/S expected to post a loss of $3.88 a share - Earnings Preview
Brief: Evaxion Biotech A/S Files For Stock Shelf Of Up To $50 Million
Brief: Nasdaq Confirms Evaxion Is Fully Compliant, Withdraws Delisting Determination
U.S. STOCKS ON THE MOVE-Brunswick, Carpenter Technology, Dover
Evaxion Biotech falls after pricing public offering
Brief: Evaxion Announces Completion Of ADS Ratio Change
Brief: Evaxion Pursues Agreement With EIB To Bolster Equity Through Conversion Of Debt Into Equity
Brief: Evaxion Announces Positive Preclinical Data For Cytomegalovirus Vaccine Program EVX-V1
Brief: Evaxion Biotech Q3 Basic EPS USD -0.04
Evaxion Biotech A/S expected to post a loss of 31 cents a share - Earnings Preview